HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Covid Working Group Chief Dr NK Arora Says World Will Depend On India For Vaccines
ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.
The 2-billion Vaccine Question: How realistic are estimates and what s the current status?
SECTIONS
Share
Synopsis
The Centre’s plan for 2 billion doses of Covid-19 vaccines by year-end depends on a massive ramp-up of production as well as flawless trials, approval and manufacturing of five new vaccines. How realistic are the estimates? In what stages are the new vaccines now?
AP
Amid a shortage of Covid-19 vaccines, which has seen many states suspend inoculation sessions, the Centre on May 13 announced that 2 billion doses would be available by the end of the year. This would be a significant leap from the approximately 80 million doses a month currently available.
Unlocking vaccine IPs provides a key
SECTIONS
Last Updated: May 06, 2021, 11:14 PM IST
Share
Synopsis
There would be two practical advantages for vaccine production in India, if the waiver comes through at the World Trade Organization.
The decision by the US to withdraw its objection to waiving patent and intellectual property rights for Covid vaccines is welcome. There would be two practical advantages for vaccine production in India, if the waiver comes through at the World Trade Organization. One, it would be simpler to extend the licences for the Astra-Zeneca, Johnson & Johnson, Sputnik V and Novavax vaccines, which have already been granted to assorted Indian vaccine makers, to more companies capable of utilising them. Two, Pune-based Gennova’s indigenous mRNA-based vaccine would be free of patent-infringement challenges, when it goes into production. India should first waive the IPR on Covaxin, or buy it out from Bharat Biotech, and transfer the knowhow to other compan